Table 1. The usage and application of anesthesia during LASIK surgery.
LASIK: laser in situ keratomileusis
| Author (year) | Primary anesthetic used | Dosage | Area of application | Post-surgery complications |
| Abdelkader et al. (2006) [10] | Ketamine hydrochloride | 50 mg/kg | Intramuscular | Ectasia |
| Asensio et al. (2003) [11] | Oxybuprocaine | 0.4% | Topical | Changes to corneal thickness |
| Buratto and Ferrari (1997) [12] | Oxybuprocaine | 4% | Topical | Hyper/hypo correction |
| Demirok et al. (2013) [13] | Proparacaine | 0.5% | Topical | Dry eye |
| Donnenfeld et al. (2003) [14] | Proparacaine | 1% | Topical | Dry eye |
| Donnenfeld et al. (2004) [15] | Proparacaine | 1% | Topical | Loss of corneal sensation |
| Edelhauser (2000) [16] | Lidocaine | 1% | Intraocular | N/A |
| Elder et al. (2000) [17] | Lignocaine | 4% | Topical | N/A |
| Gunton and Armstrong (2010) [18] | N/A | N/A | Topical | Diplopia |
| Konomi et al. (2008) [19] | Oxybuprocaine | 0.4% | N/A | Dry eye |
| Lam et al. (2012) [20] | Proparacaine | 0.5% | Topical | N/A |
| Leaming (2003) [21] | Lidocaine | N/A | Topical | N/A |
| Leaming (2004) [22] | Lidocaine | N/A | Topical | N/A |
| Li et al. (2013) [23] | N/A | N/A | Topical | Dry eye |
| Magli et al. (2009) [24] | Oxybuprocaine | 2% | Topical | Esotropia |
| Mahfouz and Khalaf (2005) [25] | Propofol/fentanyl (P/F) and ketamine/midazolam (K/M) | N/A | Topical | N/A |
| Moshirfar et al. (2014) [26] | Tetracaine and proparacaine | 0.5% both | Topical | N/A |
| Nucci and Drack (2001) [27] | Oxybuprocaine or lidocaine | 2% | Topical | Uveitis |
| Ortak et al. (2013) [28] | Proparacaine | 0.5% | Topical | Thinner cornea |
| Oshika et al. (1999) [29] | N/A | N/A | Topical | Posterior capsular rupture |
| Oshika et al. (2000) [30] | N/A | N/A | Topical | Posterior capsular rupture |
| Oshika et al. (2001) [31] | N/A | N/A | Topical | Displacement of the vitreous |
| Patel et al. (2008) [32] | Bupivacaine | 10% | Topical | None |
| Paysse et al. (2003) [33] | Halothane/nitrous oxide | N/A | Topical | None |
| Primack et al. (2001) [34] | Sevoflurane | N/A | Topical | Monocular diplopia |
| Sachdev et al. (2002) [35] | N/A | N/A | Topical | Epithelial defects |
| Saed and Abdrabbo (2011) [36] | Ketamine | 1.5–2 mg/kg | Intravenous | None |
| Solomon et al. (2003) [37] | N/A | N/A | Topical | Lamellar flap |
| Tanaka et al. (2004) [38] | Oxybuprocaine | 0.4% | Topical | Dry eye |
| Terry and Ousley (2006) [39] | Proparacaine | N/A | Topical | Disk dislocation |
| Toda et al. (2001) [40] | Oxybuprocaine | 0.4% | N/A | Dry eye |
| Toda et al. (2002) [41] | Oxybuprocaine | 0.4% | N/A | Dry eye |
| Wang et al. (2014) [42] | Proparacaine | 0.5% | Topical | Respiratory depression, hypoxemia, apnea |
| Xu and Yang (2014) [43] | Ofloxacin | 0.3% | N/A | Dry eye |
| Yin et al. (2007) [44] | Oxybuprocaine | 0.4% | Topical | N/A |
| Yoon et al. (2009) [45] | N/A | N/A | Topical | Dry eye |